Dr. Siddikuzzaman

Clinical Pathologist / Associate Coordinator


Awarded Ph.D in Biotechnology from Karunya University, Coimbatore, Tamil Nadu, India. The rationale of the work was that the poor efficiency of existing chemotherapeutic drug called all trans retinoic acid (ATRA) towards solid cancers, while ATRA is the first choice drug for APL treatment. So, I have analysed the efficiency enhancement of ATRA in a liposome encapsulation formulation (DSPC:CHL) in an experimental lung cancer C57/BL6 mice model. I was awarded DBT-Post Doctoral Fellow at Indian Institute of Science (IISc), Bangalore, Karnataka, India. My main focus was mainly analyzing the anti-cancer activity and drug toxicity of various synthetic drugs prepared by the project collaborators in various mammalian cell lines and human cells lines for eg. glioma (brain cancer) cell lines, HeLa, MCF7, B16 cells line so on as well in mice model (Balb/c and nude mice). 

I have also worked ChanRe research center in Bangalore, India where I was mainly involved in protocol developing for the research lab, preparing proposal and grant applications. I have also worked at Stempeutics Research Pvt Ltd, Bangalore, India in R&D department as a Research Scientist. I have also worked to find key biomarker which regulates the suppresses properties of hMSC in different experiments and also developed animal model for the same. I have also worked at Tata Medical center, Kolkata, India where I was purely engaged with translational study in patient tissues and cell lines/pre-clinical models to study effect of hyperthermia on DNA damage response and immune cell infiltrates in HR stratified EOCs. I have also worked as Visiting Researcher at Prof Nicola Curtin’s lab, Professor of Experimental Cancer Therapeutics, Northern Institute of Cancer Research, Newcastle University, UK to test the hypothesis that underpins the efficacy of hyperthermic intraperitoneal chemotherapy.